Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 多克隆抗體
  4. SLC13A5 Antibody, Biotin conjugated

SLC13A5 Antibody, Biotin conjugated

  • 中文名稱：
    SLC13A5兔多克隆抗體, Biotin偶聯(lián)
  • 貨號：
    CSB-PA768239LD01HU
  • 規(guī)格：
    ￥880
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品名稱：
    Rabbit anti-Homo sapiens (Human) SLC13A5 Polyclonal antibody
  • Uniprot No.：
  • 基因名：
    SLC13A5
  • 別名：
    Na(+)/citrate cotransporter antibody; NaC2/NaCT antibody; NaCT antibody; Novel solute carrier family 13 (sodium dependent dicarboxylate transporter) (Slc13a2 or 3) member antibody; S13A5_HUMAN antibody; Slc13a5 antibody; Sodium coupled citrate transporter antibody; Sodium-coupled citrate transporter antibody; Sodium-dependent citrate transporter antibody; Solute carrier family 13 (sodium dependent citrate transporter); member 5 antibody; Solute carrier family 13 member 5 antibody
  • 宿主：
    Rabbit
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human Solute carrier family 13 member 5 protein (156-204AA)
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Biotin
  • 克隆類型：
    Polyclonal
  • 抗體亞型：
    IgG
  • 純化方式：
    >95%, Protein G purified
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA
  • Protocols：
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評價

靶點詳情

  • 功能：
    High-affinity sodium/citrate cotransporter that mediates citrate entry into cells. Transports citrate in a Na(+)-dependent manner, transport process is electrogenic and recognizes the trivalent form of citrate rather than the divalent form. Although citrate is its main substrate, other intermediates of the citric acid cycle, such as succinate, fumarate, malate, oxaloacetate and alpha-ketoglutarate can serve as substrates but with a much lower affinity compared to citrate. Shows a substrate sensitivity in the order of citrate > malate ~ alpha-ketoglutarate > succinate ~ fumarate > oxaloacetate ~ isocitrate. Shows substantial citrate transporter activity when sodium ions are replaced by either potassium or choline ions. Transport activity is potentiated by lithium ions in the presence of low concentrations of citrate but is inhibited by lithium ions in the presence of high concentrations of citrate. Involved in the regulation of citrate levels in the brain.
  • 基因功能參考文獻：
    1. SLC13A5 is the second major gene associated with the clinical diagnosis of KTZS. PMID: 27600704
    2. Data suggest that SLC13A5 plays a role in progression/cell proliferation of human hepatocellular carcinoma cells; here, RNA interference using shRNA against SLC13A5 decreased tumor burden in treatment of hepatocarcinoma in a xenograft tumor model in nude mice. PMID: 28655760
    3. Data suggest that SLC13A5 plays a role in progression/proliferation of human hepatocellular carcinoma cells; RNA interference using shRNA against SLC13A5 decreased tumor burden in treatment of hepatocarcinoma in a xenograft tumor model in nude mice. [REVIEW] PMID: 28821606
    4. Study identified additional SLC13A5 mutations in patients with chronic epilepsy starting in the neonatal period, with the mutations producing inactive Na+/citrate transporters. PMID: 27261973
    5. Studies show that SLC13A5 is a transporter in the plasma membrane that mediates the uptake of citrate into cells. It is expressed in hepatocytes, neurons, and spermatozoa. Its loss-of-function mutations are associated with neonatal epilepsy in humans. This is a single-gene disease with epilepsy resulting solely from the inactivity of SLC13A5. [review] PMID: 28264506
    6. In infants presenting with therapy resistant seizures in the first days after birth, without a clear history of hypoxic-ischemic encephalopathy, but with Punctate White Matter Lesions on their neonatal MRI, a diagnosis of SCL13A5 related epileptic encephalopathy should be considered. PMID: 27913086
    7. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5). PMID: 26620127
    8. Eight patients from four families with SLC13A5 mutation are described. They have neonatal epilepsy, tooth hypoplasia, and developmental delay. PMID: 26384929
    9. SLC13A5 is a novel target gene of PXR and may contribute to drug-induced steatosis and metabolic disorders in humans. PMID: 25628225
    10. Screening of 68 additional unrelated individuals with early-onset epileptic encephalopathy for SLC13A5 mutations led to identification of one additional subject with heterozygous mutations of SLC13A5 and a similar clinical presentation as index subjects PMID: 24995870
    11. Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) PMID: 20379614
    12. This paper describes the cloning and functional characterization of the human Na(+)-coupled citrate transporter (NaCT). PMID: 12445824
    13. mediates the utilization of extracellular citrate for fat synthesis in human liver cells, and that the process is stimulated by lithium PMID: 12826022
    14. Expression and function of NaCT in a cell line and in primary hepatocytes. PMID: 16973915

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Epileptic encephalopathy, early infantile, 25 (EIEE25)
  • 亞細(xì)胞定位：
    Cell membrane; Multi-pass membrane protein.
  • 蛋白家族：
    SLC13A/DASS transporter (TC 2.A.47) family, NADC subfamily
  • 組織特異性：
    Expressed most predominantly in the liver, with moderate expression detectable in the brain and testis.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 23089

    OMIM: 608305

    KEGG: hsa:284111

    STRING: 9606.ENSP00000406220

    UniGene: Hs.399496